Prestige Consumer Healthcare (NYSE:PBH) Downgraded to Hold Rating by StockNews.com

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a research note issued to investors on Thursday.

Other research analysts have also recently issued research reports about the stock. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $85.25.

Prestige Consumer Healthcare Trading Up 0.4 %

NYSE:PBH opened at $78.58 on Thursday. Prestige Consumer Healthcare has a 52 week low of $58.22 and a 52 week high of $86.36. The firm has a 50 day moving average of $80.52 and a 200 day moving average of $74.53. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 2.08 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the prior year, the company posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last 90 days. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC grew its position in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares in the last quarter. nVerses Capital LLC lifted its holdings in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank lifted its holdings in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.